Clinical trials: Resectable Esophageal Squamous Cell Carcinoma
Oesophageal Squamous Cell Carcinoma
NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma
The investigators will conduct a prospective, single-arm study to evaluate the safety and feasibility of neoadjuvant therapy with anti-PD-L1 antibody (SHR-1316, Hengrui Medicine) in patients with resectable esophageal squamous…
- Trial name
- NATION1907II (NCT04215471)
- Testing
- PD-L1 Antibody SHR-1316
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy
Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the outcomes and identify predictors of neoadjuvant anti-PD-1 plus chemotherapy in locally advanced resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT05740995
- Testing
- neoadjuvant anti-PD-1 plus chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Resectable Esophageal Squamous Cell Carcinoma
A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma
The purpose of this study is to observe and evaluate the efficacy and safety of SHR-1210 for adjuvant treatment of resectable esophageal squamous cell carcinoma
- Trial name
- NCT04533490
- Testing
- SHR-1210
- Volunteers
- 42 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Esophageal Squamous Cell Carcinoma
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma
This is a study to evaluate the efficacy and safety of preoperative treatment with durvalumab combined with neoajuvant therapy (carboplatin, paclitaxel with/without radiation) in locally advanced resectable oesophageal squamous…
- Trial name
- NCT04568200
- Testing
- Durvalumab, Carboplatin, Paclitaxel
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
In the past few decades, surgery, radiotherapy, chemotherapy and other treatments were continuously improved, however, the mortality of esophageal squamous cell carcinoma patients was not significantly decreased.
- Trial name
- NCT07244978
- Testing
- Ivonescimab（AK112), Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy, Esophagectomy, Sample
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Esophagus Cancer
Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma
Tislelizumab in resectable esophageal squamous cell carcinoma
- Trial name
- NCT06692270
- Testing
- Tislelizumab
- Volunteers
- 20 people
- Sponsor
- Fujian Cancer Hospital
Esophageal Cancer
Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
Study Title: Observing Clinical Consistency of Personalized Neoadjuvant Therapy Using Patient-Derived Organoid Models (PDO) in Resectable Esophageal Squamous Cell Carcinoma Goal: This study aims to explore whether patient-derived…
- Trial name
- NCT07054086
- Testing
- Neoadjuvant Chemotherapy (NACT)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Esophageal Squamous Cell Carcinoma
Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
The objective is to investigate the efficacy and safety of envafolimab combined with chemotherapy for preoperative neoadjuvant therapy in patients with resectable esophageal squamous cell carcinoma
- Trial name
- NCT05552651
- Testing
- Envafolimab, Albumin-Bound Paclitaxel, Carboplatin
- Volunteers
- 40 people
- Sponsor
- Tao Jiang
Esophageal Squamous Cell Carcinoma (ESCC)
Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC
Esophageal cancer is a malignant tumor with high incidence rate and mortality in China. According to the data of the World Health Organization, 324000 new cases and 301000 deaths of esophageal cancer will occur in China in 2020…
- Trial name
- NCT06861777
- Testing
- Adebrelimab + paclitaxel/nab-paclitaxel + cisplatin followed by chemoradiotherapy, chemoradiotherapy followed by adebrelimab + paclitaxel/nab-paclitaxel + cisplatin, TNT treatment [TNT group one (phase 2) or TNT group two (phase 2)]
- Where
- China
- Volunteers
- 474 people
- Sponsor
- YIN LI
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma
China with high incidence of esophageal cancer, the number of new cases and deaths account for about 50% of the world every year.
- Trial name
- NCT04666090
- Testing
- Carillizumab, Esophagectomy, Samples
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Resectable Esophageal Squamous Cell Carcinoma
Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer
Evaluating the efficacy and safety of PD-L1 (Programmed Death-L1)antibody combined with endoscopy and radiotherapy for inoperable cT1b-2 (clinical stage tumor 1b-2) esophageal squamous cell carcinoma
- Trial name
- NCT06599775
- Testing
- Adebrelimab injection, Albumin-Bound Paclitaxel, Carboplatin injection
- Volunteers
- 42 people
- Sponsor
- Shanghai Zhongshan Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC
This multicenter, prospective Phase II study investigates a response-adapted organ-preservation strategy in patients with resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- SCOPE (NCT07711470)
- Testing
- Sugemalimab and Chemotherapy, Nab-paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Neoadjuvent, PD-1 Inhibitor
Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
The aim of this study was to investigate the efficacy and safety of pembrolizumab combined with albumin paclitaxel and cisplatin versus albumin paclitaxel and cisplatin or 5-fluorouracil and cisplatin in neoadjuvant therapy for…
- Conditions
- Neoadjuvent, PD-1 Inhibitor, Chemotherapy, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06006650
- Testing
- Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
- Where
- 3 sites in China
- Volunteers
- 114 people
- Sponsor
- Tang-Du Hospital
Esophageal Cancer
dCRT vs. Surgery in Resectable ESCC Patients Achieving cCR/PR After Induction Chemoimmunotherapy
This study is evaluating two treatment approaches for patients with locally advanced, resectable esophageal squamous cell carcinoma (ESCC) who have a good response to 2-3 cycles of induction chemoimmunotherapy.
- Trial name
- SORT (NCT07162506)
- Testing
- Surgery, Radiotherapy, Chemotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Squamous Cell Carcinoma Stage cT3-4aN0-1M0
Comparison Between NCRT and NCT Followed by MIE for Treatment of Locally Advanced Resectable ESCC
The purpose of this study is to evaluate the outcomes of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy on patients with locally advanced resectable esophageal squamous…
- Trial name
- ESCCNCRTvNCT (NCT03001596)
- Testing
- Neoadjuvant Chemoradiotherapy, Neoadjuvant Chemotherapy, Minimally Invasive Esophagectomy
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Shanghai Zhongshan Hospital
Esophageal Squamous Cell Carcinoma, Oligometastatic Disease
Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC
At present, there are relatively clear treatment guidelines for colorectal cancer with oligometastases, while the treatment mode for resectable esophageal cancer with oligometastases is not clear and there is a lack of research…
- Trial name
- LEO (NCT05951127)
- Testing
- Esophagectomy
- Where
- 2 sites in China
- Volunteers
- 141 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Carcinoma, Squamous Cell, Oral Cancer
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
Participants in this study have a type of cancer called squamous cell carcinoma of the head and neck (SCCHN). Their SCCHN has spread around the area where the cancer first started. This is called locally-advanced SCCHN.
- Conditions
- Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer, Larynx Cancer
- Trial name
- NCT03174275
- Testing
- Durvalumab, Carboplatin, Nab-paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Esophageal Squamous Cell Carcinoma
Prospective Trial to Evaluate the Safety and Efficacy to Treat Esophageal Cancer Using 5-FU, Oxaliplatin, and Docetaxel
The current multicenter prospective phase II study aims to evaluate the safety and efficacy of preoperative FLOT therapy for esophageal squamous cell carcinoma.
- Trial name
- NCT04699994
- Testing
- FLOT therapy
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- Keio University
Esophageal Cancer
A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC
The purpose of this study is to observe and evaluate the efficacy and safety of camrelizumab combined with albumin paclitaxel and cisplatin as perioperative treatment of advanced esophageal squamous cell.
- Trial name
- NCT05182944
- Testing
- A：non-pCR patients, B：non-pCR patients, A：pCR patients
- Where
- China
- Volunteers
- 130 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Resectable Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
This trial is conducted in patients with resectable locally advanced esophageal squamous cell carcinoma. The investigators plan to enroll 46 patients with resectable locally advanced esophageal cancer in Tianjin cancer hospital.
- Trial name
- NCT07457528
- Testing
- HLX10, Chemotherapy, Nimotuzumab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital